Ozempic Stomach Paralysis & Vision Loss Lawsuits

Injury claims for those suffering gastroparesis or vision loss after taking the drugs Ozempic, Mounjaro and Wegovy.

  • Fast and easy case evaluation
  • Help available in all 50 states
  • No costs to file a case unless you win
  • Speak with an attorney today.

Lawsuits have been organized into a special multidistrict litigation court. Those who’ve suffered these injuries after taking the drugs may qualify:

  • Gastroparesis (stomach paralysis)
  • Paralytic ileus (intestinal paralysis)
  • Vision loss
  • Non-arteritic Anterior Ischemic Optic Neuropathy
  • Stomach surgery.
LEARN MORE ABOUT YOUR RIGHTS

Free Case Review

Our attorneys specialize in medical device litigation. "The free evaluation is always confidential."

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Each year more than 5 million people take Ozempic, Wegovy or Mounjaro for type 2 diabetes or weight loss. Unfortunately, new reports show an increased risk of gastrointestinal conditions like stomach paralysis (gastroparesis), intestinal paralysis (paralytic ileus) or a rare disorder causing vision loss.

gastroparesis lawsuit

Ozempic, Wegovy and Mounjaro: Stomach Paralysis & Vision Loss Dangers

Gastroparesis and ileus are disorders that affect the nerves and muscles in the stomach or intestines.These can result in a number of side effects, including:

  • Repeated uncontrollable vomiting
  • An inability to digest normal amounts of food
  • Stomach pain or esophageal burning
  • Malnutrition.

Both conditions can last for years after patients stop taking the medications, and, in some cases require stomach or intestinal surgery to improve digestion.  

Experts from the National Institutes of Health, American Society of Anesthesiologists and FDA have all noted gastroparesis among people taking drugs like Ozempic, Wegovy and Mounjaro. 

Researchers also recently noted an increased risk of an eye condition called non-arteritic anterior ischemic optic neuropathy (NAION) among patients taking semaglutide drugs like Ozempic, Wegovy or Mounjaro. 

This rare disorder causes sudden vision loss in one eye due to a loss of blood flow to the optic nerve. A JAMA Ophthalmology study of 16,827 patients published in July 2024 found those taking semaglutide drugs were 4 to 7 times more likely to develop NAION.  

Although the makers of Ozempic, Wegovy and Mounjaro have known about these GI and vision risks for years, they failed to warn users and continue to downplay the dangers.

Do I Qualify for an Ozempic, Wegovy or Mounjaro Lawsuit?

Ozempic, Wegovy and Mounjaro all work by triggering the GLP-1 hormone that is normally released after a meal to let the brain know the digestive system is full. They also slow the stomach’s ability to clear food, making patients feel full longer. 

The FDA has received a growing number of reports that some patients have more extreme and longer lasting slowing of their stomach functions, resulting in gastroparesis or ileus. 

Surprisingly, the manufacturers didn’t warn patients or doctors of this danger. In fact, they downplayed the risks and instead blame it on a side effect of diabetes. 

In addition, doctors have received mounting reports of semaglutide patients suffering a rare but permanent vision loss called NAION that is caused by loss of blood flow to the optic nerve. Again, the manufacturers never warned patients of these dangers.  

As a result, lawyers believe the manufacturers will be liable for significant damages to victims, and have begun filing lawsuits on behalf of those injured. 

If you or a loved one have suffered vision loss or been diagnosed with gastroparesis after taking Ozempic, Wegovy or Mounjaro, you may qualify for a lawsuit.  

For more information on the Ozempic lawsuits for gastroparesis, ileus or vision loss, or to discuss your case and legal options directly with a lawyer, contact us today.

Free Case Review

Timeline of Ozempic Lawsuits

Latest Information on the Ozempic Litigation

2024
July
JAMA publishes study showing significantly increased risk of vision loss from NAION in patients taking semaglutide drugs.
2024
Feb
Judicial Panel on Multidistrict Litigation consolidates Ozempic and Mounjaro lawsuits to U.S. District Judge Gene E.K. Pratter in the Eastern District of Pennsylvania.
2023
August
First lawsuits filed against Novo Nordisk and Eli Lilly over gastroparesis inpatients taking Ozempic, Wegovy or Mounjaro.
2023
June
American Society of Anesthesiologists warns patients taking Ozempic, Wegovy or Mounjaro should stop before elective surgery due to slower stomach function.
2022
June
5 million prescriptions written for Ozempic and similar drugs.
2022
Mounjaro approved by the FDA for diabetes.
2021
Wegovy approved by the FDA for weight loss.
2017
A NIH study finds people taking GLP-1 agonist drugs had significantly slower digestion than those who took a placebo.
2017
Ozempic approved by the FDA for diabetes.

Is there an Ozempic, Wegovy or Mounjaro Class Action Lawsuit?

No. Instead of organizing claims under one large class action lawsuit, a federal panel of judges created a special court where individual cases can be handled at the same time.

On February 2, 2024, the Judicial Panel on Multidistrict Litigation ordered all federal lawsuits alleging Ozempic, Mounjaro or Wegovy gastroparesis injuries to be consolidated into one court so that they may be handled more quickly and fairly. 

This court is known by the formal name MDL 3094 In Re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAS) Products Liability Litigation. It is located in the U.S. District Court in the Eastern District of Pennsylvania and is presided over by Judge Karen S. Marston. 

Instead of creating a single class action lawsuit for Ozempic injuries, the MDL court allows those affected to band their individual cases together to seek damages against the company. 

This multidistrict litigation court (MDL) process is actually more beneficial for consumers than a class action lawsuit. In a class action lawsuit, a group of lawyers will gather together class participants who must share whatever is awarded. However, individual participants in an MDL can select their own lawyer, exercise more control over their case and whether it settles, and reap higher award amounts for their separate lawsuit.

Lawyers expect thousands of lawsuits will eventually be filed in the Ozempic/Mounjaro/Wegovy MDL court. 

DrugNews works only with lawyers that are integrally involved in defective drug MDL litigation or are active on the influential MDL Plaintiff Steering Committees.

Choosing an Ozempic Gastroparesis Lawyer

If you or a loved one have been diagnosed with gastroparesis or vision loss after taking Ozempic, Wegovy or Mounjaro, it’s important to have your case examined by a legal expert to see if you have the right to recover damages.  

Our qualified prescription drug injury lawyers will fully investigate your case, reviewing medical records, safety warnings and recent studies that your doctor may not normally discuss.  

Most states allow you several years to file a lawsuit after you suffer an injury or discover it may be linked to a dangerous product. However, you should begin the process as early as possible to make sure your lawyer has time to get necessary records and prepare your case.   

DrugNews works only with attorneys and law firms that have successfully handled tens of thousands of lawsuits involving injury or death from drugs and medical devices. And, we can connect you directly to a lawyer or patient advocate today, so you’ll be able to decide if you want to proceed.   

We make it easy to get help, find out if you qualify, and quickly file a claim. Our service is offered at no cost to you, and you won’t pay anything to your attorney unless you receive an award. Also, our qualified lawyers can handle most aspects of your case without you ever having to leave your home.   

For more information, or to learn about your options - call, chat or email us today.

Free Case Review

Our attorneys specialize in medical device litigation. "The free evaluation is always confidential."

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Sources of information

Get in touch with us.

Call, email or live chat with us today to see how we can help.

call DrugNews.net
Need a quick answer? Call us!
email DrugNews.net
Reach out to us by email.
live chat with DrugNews
We are here to help now